diabetes type News
-
“High Treatment Satisfaction with 3-day Insulin Patch is Independent of Patient Demographics: A Post-Hoc Analysis” — a presentation at the American Diabetes Association 80th Scientific Sessions
Progression of Type 2 Diabetes Treatment Due to natural progression of type 2 diabetes, maintenance of glycemic targets requires a stepwise approach to treatment in order to achieve and maintain glycemic control and avoid complications1'2 Comprehensive lifestyle modifications combined with metformin Addition of up to 3 oral medications or GLP-1 RA injection Addition of basal (long-acting) ...
-
Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent diabetes, has secured a grant of $69,000 from Canadian Glycomics Network (GlycoNet) to expand and validate the model for its lead drug candidate “ZT-01” from type 1 diabetes (T1D) to type 2 diabetes ...
-
Peptides for Diabetes Research—a Special Offer of BOC Sciences
BOC Sciences has been constantly enriching its peptide product library for years. Its peptides for diabetes research are recently brought into focus due to the growing concerns on this problem According to data from the WHO, a large number of adults are having diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia. The absolute lack of insulin, due to destruction of the ...
By BOC Sciences
-
Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist
Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic ...
-
Aspect Biosystems To Present New Data At International Pancreas And Islet Transplant Association (Ipita) Congress 2021
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and ...
-
Biocon Biologics Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus Device Patents
Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Court of Appeals for the Federal Circuit (USCAFC) has upheld the U.S. Patent and Trademark Appeal Board’s decisions for unpatentability of five device patents for Sanofi’s Lantus® SoloSTAR®, as well as a district court decision on one of these patents. The Patent ...
By Biocon
-
Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 16-20, 2019 in Barcelona. The company recently undertook research to determine ...
-
NHS Long Term Plan gives thousands of life changing diabetes monitors
Nearly 30,000 people across the country with Type 1 diabetes have received life-changing diabetes monitors through the NHS Long Term Plan. The innovative device, which is the size of a £2 coin and worn on the arm, means people with Type 1 do not have to carry out multiple painful finger-prick checks to monitor their blood sugar levels. Instead, people with the condition can monitor their ...
-
Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal
Results of an analysis of a previous prevention trial with Diamyd® (GAD-alum) treatment, which indicate a positive and sustained immunomodulating effect after treatment with Diamyd® in healthy children at risk for type 1 diabetes, have been published in the scientific journal Journal of Immunology Research. The analysis was carried out by researchers at Lund University and provides ...
-
New training manual for treatment of type 1 diabetes in children in developing countries
In collaboration with the International Society for Pediatric and Adolescent Diabetes (ISPAD) Novo Nordisk has today launched a training manual specific to the diagnosis and treatment of diabetes care for children in developing countries. Unveiled on the opening day of the ISPAD Congress 'ISPAD 2010', which is currently taking place in Buenos Aires, this first edition of the manual is available ...
-
GI Dynamics Announces Approval of the I-STEP Clinical Study in India
BOSTON & HYDERABAD, India--( )-- GI Dynamics Inc., a medical device company that isBUSINESS WIRE developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, is pleased to announce that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study evaluating the safety and ...
-
Road traffic noise increases risk of diabetes
Increasing noise levels are a global environmental concern, and have been linked to important health issues, such as heart disease and cognitive development. New Danish research has now shown that it is also associated with an increased risk of diabetes. It has been estimated that approximately a third of the population of the EU is exposed to traffic noise in the home that exceeds World Health ...
-
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of AntigenSpecic Tolerance and Protect Against Type 1 Diabetes
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of comprehensive preclinical research on the SQZ® Tolerizing Antigen Carrier (TAC) platform. The data, published in Frontiers in Immunology, demonstrated that TACs can induce multiple key mechanisms of ...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Traffic pollution associated with risk of developing type 2 diabetes
Long-term exposure to traffic-related air particle pollution is linked with type 2 diabetes, a new study in Germany has found. Furthermore, the study found that people living close to busy roads were at greater risk of developing the disease than those living further away. Air pollution has been linked to a number of health problems, including heart, circulatory and lung diseases. It has also ...
-
Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), ...
-
Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
/www.w3.org/1999/xhtml">Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no ...
-
Type 2 diabetes may be linked to pesticide exposure
Cambridge University scientists are advocating more research into the possible links between environmental pollution and type 2 diabetes, the most common form of the disease. At least 171 million people worldwide suffer from diabetes, according to estimates by the World Health Organization. In today's edition of the British medical journal 'Lancet,' Drs. Oliver Jones and Julian Griffin highlight ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you